SWARCO FUTURIT Verkehrssignalsysteme GmbH. v. STRABAG Infrastructure & Safety Solutions GmbH

UPC-001022

The Local Chamber Vienna addressed an alleged infringement of European Patent 2 643 717 brought by SWARCO Futurit Verkehrssignalsysteme GmbH against STRABAG Infrastructure & Safety Solutions GmbH, with Chainzone Technology (Foshan) Co., Ltd. intervening. The court established guiding principles on four key issues: the mandatory formal counterclaim for revocation when invalidity is pleaded, the distinction between recall and final removal of infringing products, the discretionary nature of publication orders, and the cost treatment of interveners as analogous to parties.

Jurisdiction
European UPC
Court
Vienna (AT) Local Division
Case Number
UPC-001022
Decision Date
15 January 2025

Detailed Summary

The proceedings were conducted before the Local Chamber Vienna under case reference UPC_CFI_33/2024 (ACT_4261/2024), concerning European Patent 2 643 717. The claimant was SWARCO Futurit Verkehrssignalsysteme GmbH, represented by NOMOS Rechtsanwälte GmbH. The defendant was STRABAG Infrastructure & Safety Solutions GmbH, represented by SONN Patentanwälte GmbH & Co KG. Chainzone Technology (Foshan) Co., Ltd., a Chinese entity, participated as an intervener (Streithelferin), represented by Kliment & Henhapel Patentanwälte OG and Gassauer-Fleissner Rechtsanwälte GmbH.

The dispute centered on an alleged patent infringement concerning European Patent 2 643 717. The defendant raised an invalidity objection based on exceeding the original disclosure (Überschreitung der Ursprungsoffenbarung). The case also involved questions regarding the appropriate scope of remedial measures, specifically the distinction between recall of infringing products and their final removal from distribution channels. Additionally, the claimant sought publication of the decision, and the question arose regarding cost allocation as between the parties and the intervener.

& Analysis:

The court addressed four principal legal issues. First, regarding the invalidity defense, the court held that under Rule 25 of the Rules of Procedure, when a defendant alleges that the patent is invalid, the statement of defense must contain a counterclaim for revocation of the patent against the patent proprietor in accordance with Rule 42 RoP. Since the defendant failed to file such a formal counterclaim, the court declined to address the substantive invalidity objection based on exceeding the original disclosure.

Second, regarding remedies, the court distinguished between recall of infringing products and their final removal from distribution channels, holding that final removal is an independent measure separate from recall. Removal is only available where the infringer has the actual and legal means to carry it out, and the formulation of concrete and sufficiently specific measures must be oriented accordingly.

Third, regarding publication under Article 80 EPGÜ, the court held that the decision to permit publication lies within the court's discretion. For such an order to be made, the claimant's interest in publication must outweigh any adverse consequences for the defendant. Publication is generally only considered when the claimant's protection is not already ensured by other measures. The court referenced prior decisions (UPC_CFI_373/2023, SodaStream v. Aarke; UPC_CFI_16/2024, Ortovox v. Mammut) and noted that the preventive purposes of Article 80 EPGÜ (deterrence of future infringers and public awareness) must be supported by specific submissions demonstrating the preventive interest in the particular infringement case.

Fourth, regarding costs, although the Rules of Procedure contain no separate cost provision for interveners, the court derived from the principle of Rule 315.4 RoP that an intervener is to be treated like a party for cost-bearing purposes. Where the supported party loses—as in the present case—a proportionate cost contribution would be justified if the intervener's participation caused additional effort for the prevailing party. In any event, an intervener on the losing side must bear its own costs.

Final Order & Ruling:

The decision was issued on January 15, 2025, by the Local Chamber Vienna. The court established guiding principles (Leitsätze) on the four key issues: (1) the mandatory nature of a formal revocation counterclaim when invalidity is pleaded, with the consequence that unsubstantiated invalidity objections will not be addressed; (2) the distinction between recall and final removal from distribution channels as separate remedial measures; (3) the discretionary nature of publication orders under Article 80 EPGÜ requiring a balancing of interests; and (4) the cost treatment of interveners as analogous to parties under Rule 315.4 RoP.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Vienna (AT) Local Division. Understanding the court's reasoning in SWARCO FUTURIT Verkehrssignalsysteme GmbH. vs STRABAG Infrastructure & Safety Solutions GmbH is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentUPC-000530

Sibio Technology LimitedvsAbbott Diabetes Care Inc.

Sibio Technology Limited filed a revocation action against Abbott Diabetes Care Inc. seeking to revoke European patent EP 3 831 283 B1, which relates to in vivo analyte monitoring devices. Sibio challenged the patent's validity on grounds of added subject matter, lack of novelty, and lack of inventive step. The Court of First Instance of the Unified Patent Court (Central Division, Paris Seat) dismissed the revocation action, finding that the alleged grounds for invalidity were either inadmissible as late-filed or not proven, and ordered the patent to be maintained as granted with costs borne by Sibio.

patentUPC-000716

STADA Nordic ApSvsRespondent

This is a procedural order from the Local Division Munich of the Court of First Instance concerning patent infringement actions related to European Patent No. 2 493 466, which covers cabazitaxel compounds for treating prostate cancer. The claimants, multiple Sanofi entities, have brought infringement actions against several groups of defendants including Accord Healthcare, STADA, Reddy Pharma, and Zentiva entities across multiple UPC member states. The judge-rapporteur issued orders regarding the procedural schedule, including deadlines for rejoinders, closure of written procedure, interim conferences, and the oral hearing.

patentUPC-000267

Skechers USA Deutschland GmbH, Skechers S.a.r.l, Skechers U.S.A., Inc., Skechers EDC SPRL, Skechers USA Italia Srl, Skechers USA France SASvsFAST IP, LLC

FAST IP LLC brought an infringement action against multiple Skechers group entities based on European patent EP4003084 concerning rapid-entry footwear. The Defendants applied under R. 323 RoP to change the language of the proceedings from German to English, the language in which the patent was granted. The Claimant opposed the application. The President of the Court of First Instance issued an order addressing the application to change the language of the proceedings.

patentUPC-000049

Advanced Brain Monitoring, Inc.vsKoninklijke Philips N.V. Et al

This is a patent infringement action concerning European Patent EP 2 437 696 B2, owned by Advanced Brain Monitoring, Inc. (ABM), which relates to systems and methods for controlling position, particularly wearable position therapy devices for treating sleep disorders. ABM alleges that Philips' NightBalance position therapy device infringes device claims 1, 2, and 4 of the patent. The patent had previously been confirmed in amended form by the EPO Technical Board of Appeal on 25 December 2024 following opposition proceedings initiated by a Philips group member.

patentUPC-000286

ONWARD Medical N.VvsNiche Biomedical, Inc.

ONWARD Medical N.V. sought interim injunctive relief against Niche Biomedical, Inc. (doing business as ANEUVO) for alleged infringement of European Patent EP 3 421 081 B1, directed to a system for neuromodulation. The Local Chamber Munich of the Unified Patent Court addressed the legal principle that auxiliary requests seeking interim measures based on alternative claim formulations deviating from the granted patent version are generally inadmissible in provisional proceedings under Article 62 EPGÜ. The court held that a patent proprietor's request to amend the claim formulation indicates that the patent as granted is likely invalid, undermining the court's ability to assess the validity required for granting interim relief.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call